#1 Clinical Trials Search in Europe

Human Papillomavirus Type 52 L1 Protein

This article summarizes several clinical trials investigating the use of Human Papillomavirus Type 52 L1 Protein as part of the 9-valent HPV vaccine (9vHPV or Gardasil 9) for preventing HPV infections and related diseases. The trials examine the vaccine’s efficacy, safety, and immune responses in various populations, including adolescents, adults, immunocompromised individuals, and patients with HPV-related conditions. The studies explore different dosing schedules, vaccination timing, and potential therapeutic applications of the 9vHPV vaccine.

Table of Contents

Introduction

Human Papillomavirus Type 52 L1 Protein is one of the key components in the 9-valent HPV vaccine, also known as Gardasil 9. This vaccine is designed to prevent infections and diseases caused by nine types of human papillomavirus (HPV), including type 52. HPV is a common sexually transmitted infection that can lead to various cancers and genital warts.[1]

Vaccine Composition

The 9-valent HPV vaccine contains L1 proteins from nine different HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58. These proteins are produced using recombinant DNA technology in yeast cells (Saccharomyces cerevisiae). The Human Papillomavirus Type 52 L1 Protein is specifically produced in yeast cells of the strain Canade 3C-5 (Strain 1895).[1]

The L1 proteins in the vaccine are in the form of virus-like particles (VLPs). These VLPs mimic the structure of the actual virus but do not contain any genetic material, making them non-infectious. The proteins are also adsorbed onto an aluminum-containing adjuvant to enhance the immune response.[2]

Mechanism of Action

When the vaccine is administered, the L1 proteins, including the Human Papillomavirus Type 52 L1 Protein, stimulate the body’s immune system to produce antibodies against these specific HPV types. These antibodies help prevent future infections by neutralizing the virus before it can infect cells.[2]

Indications

The 9-valent HPV vaccine containing Human Papillomavirus Type 52 L1 Protein is indicated for the prevention of:

  • Persistent anogenital HPV infection
  • Cervical, vulvar, vaginal, and anal cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58
  • Genital warts caused by HPV types 6 and 11
  • Precancerous or dysplastic lesions caused by the nine HPV types covered by the vaccine[1]

Dosage and Administration

The vaccine is typically administered as a series of intramuscular injections. The dosing schedule may vary depending on the age of the recipient:

  • For individuals 9-14 years old: A 2-dose regimen is recommended, with the second dose given 6-12 months after the first dose.
  • For individuals 15 years and older: A 3-dose regimen is recommended, with the second dose given 2 months after the first, and the third dose given 6 months after the first.[1]

Recent studies are also exploring extended dosing intervals and alternative dosing schedules to optimize vaccine effectiveness and coverage.[1]

Efficacy

Clinical trials have shown that the 9-valent HPV vaccine, including the Human Papillomavirus Type 52 L1 Protein component, is highly effective in preventing infections and diseases caused by the covered HPV types. The vaccine has demonstrated:

  • High rates of seroconversion (development of antibodies) against all nine HPV types
  • Significant reduction in the incidence of HPV-related precancerous lesions
  • Long-lasting protection, with studies showing sustained antibody levels for several years after vaccination[1][3]

Safety Profile

The 9-valent HPV vaccine has been extensively tested and has shown a favorable safety profile. Common side effects may include:

  • Pain, swelling, and redness at the injection site
  • Headache
  • Fever
  • Nausea
  • Dizziness[2]

Serious adverse events are rare, and the benefits of vaccination are considered to outweigh the risks for the indicated populations.[2]

Ongoing Research

Several clinical trials are currently underway to further investigate the efficacy and potential applications of the 9-valent HPV vaccine, including the Human Papillomavirus Type 52 L1 Protein component. Some areas of ongoing research include:

  • Extended dosing intervals and alternative dosing schedules to improve vaccine coverage and effectiveness[1]
  • Efficacy in preventing oral HPV infections and related cancers in adult males[3]
  • Use of the vaccine in immunocompromised populations, such as stem cell transplant recipients[4]
  • Potential therapeutic applications for existing HPV-related conditions, such as difficult-to-treat warts[5]
  • Effectiveness of vaccination in women over 45 years old who have been treated for high-grade cervical lesions[6]

These ongoing studies aim to expand our understanding of the vaccine’s potential and optimize its use in various populations and clinical scenarios.

Study Focus Population Key Objectives Dosing Schedule
Extended dosing intervals Boys and girls 9-14 years, women 16-26 years Compare immunogenicity of 2-dose vs 3-dose regimens 2-dose (various intervals) or 3-dose standard
Immunocompromised patients Children and adolescents 9-18 years Evaluate immunogenicity in immunocompromised individuals 3-dose standard
Oral HPV prevention Adult males 20-45 years Assess efficacy in preventing oral HPV infections 3-dose standard
Post-transplant vaccination AlloSCT recipients ≥18 years Compare early vs late vaccination after transplant 3-dose standard
Vulvar HSIL treatment Women with vulvar HSIL Evaluate efficacy in preventing HSIL recurrence 3-dose standard
Cervical HSIL treatment Women >45 years with cervical HSIL Assess HPV clearance after HSIL treatment 3-dose standard
Wart treatment Patients ≥15 years with difficult-to-treat warts Evaluate efficacy in treating resistant warts 3-dose standard

FAQ

  • What is the 9vHPV vaccine? The 9vHPV vaccine, also known as Gardasil 9, is a vaccine that protects against nine types of Human Papillomavirus (HPV), including types 6, 11, 16, 18, 31, 33, 45, 52, and 58. It contains virus-like particles of the L1 protein from each of these HPV types.
  • Who is being studied in these clinical trials? The clinical trials involve various populations, including adolescents and young adults aged 9-26 years, adult males aged 20-45 years, immunocompromised children and adolescents, women with vulvar high-grade squamous intraepithelial lesions (vHSIL), and patients with difficult-to-treat palmar or plantar warts.
  • What are the main objectives of these studies? The main objectives vary across studies but generally include evaluating the vaccine's efficacy in preventing HPV infections and related diseases, assessing immune responses, comparing different dosing schedules, and investigating the vaccine's potential therapeutic effects in patients with existing HPV-related conditions.
  • How is the vaccine administered in these trials? The 9vHPV vaccine is typically administered as an intramuscular injection. Most studies use a 3-dose regimen, with some trials exploring extended 2-dose regimens with longer intervals between doses.
  • What are some of the key outcomes being measured? Key outcomes include antibody levels against HPV types, seroconversion rates, incidence of HPV infections and related diseases, safety and tolerability of the vaccine, quality of life improvements, and in some cases, clearance of existing HPV infections or regression of HPV-related lesions.

Ongoing Clinical Trials on Human Papillomavirus Type 52 L1 Protein

  • Study on HPV Vaccine Timing for Patients After Stem Cell Transplantation Using Gardasil 9

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

Glossary

  • Human Papillomavirus (HPV): A group of viruses that can cause various types of cancer and genital warts. There are many types of HPV, with some considered high-risk for causing cancer.
  • 9vHPV vaccine: A vaccine that protects against nine types of HPV (6, 11, 16, 18, 31, 33, 45, 52, and 58). It is also known as Gardasil 9.
  • L1 Protein: The major capsid protein of HPV that forms virus-like particles used in HPV vaccines to stimulate an immune response.
  • Seroconversion: The development of detectable antibodies in the blood against a specific antigen, in this case, HPV types.
  • Geometric Mean Titer (GMT): A measure of the average antibody level in a group of individuals, calculated using the geometric mean.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
  • Competitive Luminex Immunoassay (cLIA): A laboratory test used to measure antibody levels against specific HPV types.
  • High-grade Squamous Intraepithelial Lesion (HSIL): Abnormal, precancerous changes in the cells of the cervix, vulva, or other areas that may progress to cancer if left untreated.
  • Allogeneic Stem Cell Transplantation (AlloSCT): A procedure where a patient receives stem cells from a genetically similar donor to treat certain blood and immune system disorders.
  • Immunocompromised: Having a weakened immune system, which can be due to certain medical conditions or treatments.

References

  1. http://clinicaltrials.eu/trial-id/2022-500256-37-00
  2. http://clinicaltrials.eu/trial-id/2022-501413-31-00
  3. http://clinicaltrials.eu/trial-id/2022-501974-21-00
  4. http://clinicaltrials.eu/trial/study-on-hpv-vaccine-timing-for-patients-after-stem-cell-transplantation-using-gardasil-9/
  5. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-the-nonavalent-hpv-vaccine-in-treating-hard-to-treat-palmar-or-plantar-warts-in-patients-who-have-not-responded-to-two-previous-treatments/
  6. http://clinicaltrials.eu/trial/study-on-hpv-vaccine-after-treatment-for-high-grade-cervical-lesions-in-women-over-45/